TAIPEI, July 25,
2024 /PRNewswire/ -- Merdury Biopharmaceutical
Corporation (Merdury) (Taipei Exchange Stock Code: 6932) announced
today that it has signed a Memorandum of Understanding (MOU) with
Health2Sync, Asia's largest
chronic disease management platform. In this collaboration, the two
parties aim to enhance the clinical evidence supporting the
superior pharmacokinetic profile of oral semaglutide when delivered
by Merdury's StackDose™ technology. As a GLP-1 agonist, semaglutide
has demonstrated remarkable efficacy in treating diabetes and
obesity. Its exceptional weight reduction capabilities led to FDA
approval for weight management in the US in 2021, and it is rapidly
gaining popularity in the US and around the world.
In the pre-clinical trials, Merdury saw
encouraging results that the innovative formulation, which uses its
StackDose™ technology platform, significantly enhances
semaglutide's absorption and bioavailability, leading to prolonged
blood concentration and extended duration of action compared to
existing oral semaglutide formulations on the market. With the
ambition of bringing more effective treatments worldwide, Merdury
has filed patent applications for its technology in multiple
countries.
"We are excited to partner with Health2Sync in
clinical trials to demonstrate StackDose's ability to enhance the
area under the [pharmacokinetic] curve (AUC)," said Elton Liang, CEO of Merdury Biopharmaceutical
Corporation. "Health2Sync's established presence and robust
platform in Taiwan will be
instrumental in streamlining clinical trials and ultimately,
bringing our innovative therapies to patients worldwide."
Compared to existing options, Merdury's oral
tablets increases the total drug concentration in the blood by 1.5
times (AUC0-∞) and reduces the time to peak blood
concentration (Tmax) by 43%. This translates to
potentially faster efficacy for patients. To further validate these
promising results, Health2Sync will leverage its cloud-based care
platform and patient app to integrate users' continuous glucose
monitoring data for the next phase of clinical trials. This
partnership aims to demonstrate the highest levels of quality and
efficacy in the clinical trial results of StackDose™, producing the
evidence needed for licensing discussions with pharmaceutical
companies with oral GLP-1 drugs in their portfolios.
"We're thrilled to partner with Merdury and
leverage Health2Sync's platform to advance their innovative drug
delivery technology," said Ed Deng,
Co-founder and CEO of Health2Sync. "This collaboration underscores
our commitment to empowering life sciences companies with the tools
they need to accelerate clinical trials and deliver life-changing
solutions to patients struggling with glucose control or weight
management."
Health2Sync has partnered with the world's top
life sciences companies active in metabolic disease, such as
Abbott, AstraZeneca, Novo Nordisk and Sanofi, to promote digital
diabetes solutions. The key markets
cover Taiwan, Japan, South
Korea, Singapore,
Egypt, Australia, and other regions. With the
Health2Sync app, users can now view their daily glucose patterns,
record their diet and exercise diaries, and adjust the lifestyle
habits with the assistance of healthcare professionals and over 80
integrations with smart devices.
About Health2Sync
Established in 2013 in Taiwan, Health2Sync made its footprints in
Japan in 2018, generating nearly
half of its revenue from overseas operations since then. Empowering
users and healthcare professionals to effectively manage chronic
conditions through early intervention will ultimately alleviate the
financial burden on national healthcare systems. Health2Sync's
insulin dose titration software, Insultrate, received Taiwan FDA
approval as a Class II medical device in October 2023, becoming the first-ever digital
therapeutic approved in Taiwan.
This algorithmic product was recognized with the "18th National
Innovation Award - Enterprise Innovation" award, while Health2Sync
was further honored with the "NEXT BIG Startup" title by the
National Development Council in the next year. As of June 2024, Health2Sync has over 1.3 million users
worldwide.
For more information, visit
http://www.health2sync.com
About Merdury Biopharmaceutical
Corporation*:
Merdury Biopharmaceutical Corporation* was
founded in July 2019, focuses on the
development of medications for medical gaps. Merdury
Biopharmaceutical Corporation* has developed "StackDose™ new drug
technology development platform" that the new dosage tablets can
be controlled-dissolved and
absorbed at the targeted site by using a 3D powder-printing
pharmaceutical manufacturing process combined with a patented
pharmaceutical binding formulation, in addition to increasing the
bioavailability of active pharmaceutical ingredients (API) to
achieve optimal efficacy, allowing for lower drug dosage and less
side effects. The company is listed on the Emerging Stock Exchange
on December 23, 2022, with a par
value of NT$0.25 per share.
More information: https://www.merdury.com/.
Declaration:
The documents and information released at the
same time include forecast narratives. All statements regarding
Merdury Biopharmaceutical Corporation* (hereinafter referred to as
the "Company")'s future operations, probable events, and prospects
(including, but not limited to, forecasts, goals, estimates and
operating plans), other than those that relate to facts that have
already occurred, are statements of a prospective nature. Forecasts
are subject to various factors and uncertainties that may cause
them to differ materially from the actual situation. These factors
include, but are not limited to, price fluctuations, actual demand,
changes in foreign exchange rates, market share, market
competition, changes in legal, financial, and regulatory
frameworks, international economic and financial market conditions,
political risks, cost estimates, and other risks and variables
beyond the Company's control. These forward-looking statements are
based on current projections and evaluations, and the Company is
not responsible for future updates.
View original
content:https://www.prnewswire.com/news-releases/merdury-signs-mou-with-health2sync-to-conduct-trial-of-merdurys-stackdose-technology-intended-for-usage-in-glp-1-semaglutide-medication-302205498.html
SOURCE Health2Sync